Individuals bought a net KRW 56.2 billion of SK Bioscience… sold a net KRW 485.3 billion for Celltrion
[Newsmp] In the midst of the COVID-19 pandemic, individual investors who have been big fans of pharmaceutical stocks have lost their interest.
According to the Korea Exchange, the sales of individual investors on 46 pharmaceutical stocks in the securities market were about KRW 472.6 billion, more than the purchase amount in the third quarter.
Individual investors who net sold nearly KRW 500 billion of pharmaceutical index constituents during this period concentrated on SK Bioscience and Ildong Pharmaceutical.
In the third quarter, individual investors’ net purchase of SK Bioscience was KRW 56.2 billion, the only one to exceed KRW 50 billion, followed by Ildong Pharmaceutical with KRW 44.5 billion.
With SK Bioscience and Ildong Pharmaceutical, five stocks surpassed KRW 10 billion with KRW 26.6 billion for GC Pharma, KRW 13.4 billion for Bukwang Pharmaceutical, and KRW 11.5 billion for Hanmi Pharmaceutical.
On the other hand, individual investors net sold close to KRW 500 billion (KRW 485.3 billion) of Celltrion, KRW 134.5 billion of Samsung Biologics, and KRW 25.3 billion of Daewwong Pharmaceutical, exceeding KRW 10 billion.
While individual investors sold a net of nearly KRW 500 billion, institutional investors bought a net of KRW 350 billion.
In particular, they focused on two stocks, the net purchase of Samsung Biologics with KRW 231.5 billion, and Celltrion with KRW 231 billion.
There were no other stocks with net purchases of more than KRW 10 billion by institutional investors.
On the contrary, institutional investors net sold KRW 53.4 billion of Hanmi Pharmaceutical, KRW 27.7 billion of Yuhan Corporation, and KRW 21.5 billion of GC Pharma.
Meanwhile, foreign investors bought a net KRW 100 billion of pharmaceutical index stocks.
Net purchases of Celltrion amounted to KRW 248.9 billion, Hanmi Pharmaceutical KRW 41.5 billion, Yuhan Corporation KRW 34.5 billion, and Daewoong Pharmaceutical about KRW 25.5 billion.
However, foreign investors sold a net KRW 84.6 billion of Samsung Biologics, KRW 55.5 billion of SK Bioscience, and KRW 46.3 billion of Ildong Pharmaceutical.
